Weiwei Ge
Impact in
- Infectious Diseases top 10%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Viral Infections and Vectors
-
- interferon and immune responses
Papers in
-
- SARS-CoV-2 and COVID-19 Research 3
- Viral gastroenteritis research and epidemiology 1
-
- MicroRNA in disease regulation 2
- Cancer-related molecular mechanisms research 2
- Journals
- PLoS Pathogens (2 papers)Scientific Reports (1 paper)Bioresource Technology (1 paper)Gene (1 paper)European Journal of Cancer (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Weiwei Ge
11 papers receiving 352 citations
Peers
Comparison fields: 5 of 62
- Infectious Diseases 134
- Immunology 96
- Cancer Research 64
- Pathology and Forensic Medicine 38
- Clinical Biochemistry 14
Countries citing papers authored by Weiwei Ge
This map shows the geographic impact of Weiwei Ge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiwei Ge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiwei Ge more than expected).
Fields of papers citing papers by Weiwei Ge
This network shows the impact of papers produced by Weiwei Ge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiwei Ge. The network helps show where Weiwei Ge may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Weiwei Ge, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 5 | |
| 4 | 2024 | 7 | |
| 5 | 2023 | 12 | |
| 6 | 2023 | 1 | |
| 7 | 2022 | 18 | |
| 8 | 2022 | 60 | |
| 9 | 2021 | 48 | |
| 10 | 2020 | 128 | |
| 11 | Expression and functional perspectives of miR-184 in pancreatic ductal adenocarcinoma. | 2015 | 12 |
| 12 | 2011 | 61 |
About Weiwei Ge
Weiwei Ge is a scholar working on Infectious Diseases, Cancer Research, Clinical Biochemistry, Complementary and alternative medicine and Molecular Biology, having authored 12 papers that have together received 354 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (3 papers), interferon and immune responses (2 papers), MicroRNA in disease regulation (2 papers), Cancer-related molecular mechanisms research (2 papers), Gut microbiota and health (2 papers), Viral gastroenteritis research and epidemiology (1 paper), Ginseng Biological Effects and Applications (1 paper) and Metabolomics and Mass Spectrometry Studies (1 paper). The work is most often cited by research in Infectious Diseases (134 citations), Immunology (96 citations), Cancer Research (64 citations), Pathology and Forensic Medicine (38 citations) and Clinical Biochemistry (14 citations). Weiwei Ge has collaborated with scholars based in China and United States. Frequent co-authors include Jianguo Wu, Pan Pan, Keli Chen, Wenbiao Wang, Xiaoping Geng, He Li, Feng Xiao, Kailang Wu, Dingwen Hu and Mingfu Tian. Their work appears in journals such as PLoS Pathogens, Scientific Reports, Bioresource Technology, Gene and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.